US OptionsDetailed Quotes
MOR240517P20000
- 1.05
- 0.000.00%
15min DelayTrading May 17 12:03 ET
0.00High0.00Low
0.00Open1.05Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover993.86%IV3.16%PremiumMay 17, 2024Expiry Date1.63Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.7242Delta0.2180Gamma17.50Leverage Ratio-10.8081Theta0.0000Rho-12.67Eff Leverage0.0005Vega
MorphoSys Stock Discussion
Sign in to post a comment
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
5
1
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
10
1
$MorphoSys(MOR.US$ MorphoSys Spokesperson Says "This Story Is Factually Wrong" In An Emailed Statement To Bloomberg News, In Response To STAT News' Adam Feuerstein Article Entitled, "Why Novartis Is Going To Walk Away From Its Acquisition"
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...
1
3
Palantir's Q4 commercial business performance was 'bombastic, baller, incomprehensibly good', according to CEO Alex Karp. Coherent sees 'improving demand trends', expecting 'ongoing sequential improvement in revenue growth'. Chegg's Q1 guidance disappointed investors. NXP Semiconductors' Q4 results surpassed expectations. Novartis' acquisition of MorphoSys is viewed positively.
3
1
3
4
$MorphoSys(MOR.US$ buying some here looks good
No comment yet
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long